中国泰凌医药集团
CHINA NT PHARMA GROUP

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1011)

CHANGE OF CHIEF EXECUTIVE OFFICER

RESIGNATION OF CHIEF EXECUTIVE OFFICER

The board (the "**Board**") of directors (the "**Director(s)**") of China NT Pharma Group Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that Mr. Zhang Bozhi ("**Mr. Zhang**") has resigned from his position as the chief executive officer as he wishes to devote more time to his personal and other affairs, with effect from 3 July 2026. Upon his resignation, Mr. Zhang ceased to hold any position with the Company or any of its subsidiaries. Mr. Zhang has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company (the "**Shareholders**").

The Board would like to express its sincere gratitude to Mr. Zhang for his contribution to the Group during his tenure of service as the chief executive officer.

APPOINTMENT OF CHIEF EXECUTIVE OFFICER

The Board is pleased to announce that Mr. NG, Andy Ching Kit (吳靜杰) ("**Mr. NG**") has been appointed as the chief executive officer of the Company with effect from 3 July 2026.

The biographical details of Mr. NG are set out below:

Mr. NG, aged 35, studied at the University of Texas in the United States and has studied overseas for a number of years. He has nearly 15 years of extensive experience in the pharmaceutical industry through his previous positions at various well-known multinational pharmaceutical enterprises, including the pharmaceutical business department of Pfizer Hanhui and the vaccine business department of GlaxoSmithKline. Mr. NG joined the Company in 2018 and has held core positions such as international business manager and general manager. From August 2020 to December 2024, he served as the general manager of the international business department of an associate of the Company. Going forward, Mr. NG will lead the development of the Company's new business model, introduce an advanced commercial framework for pharmaceutical technologies, establish a new-generation operating model, and drive the Company into a new stage of development.

Mr. NG is the son of Mr. Ng Tit, the controlling shareholder, Chairman of the Board and an executive Director of the Company, and Ms. Chin Yu, the controlling shareholder and a non-executive Director of the Company. Mr. NG is also the elder brother of Ms. Ng Anna Ching Mei, an executive Director of the Company, and the nephew of Dr. Qian Wei, a non-executive Director of the Company (Dr. Qian Wei is the brother of Ms. Chin Yu).

Save as disclosed above, Mr. NG does not have any relationship with any other Directors, senior management, substantial shareholders (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) or controlling shareholders (as defined in the Listing Rules) of the Company. Mr. NG has not held any directorships in other listed public companies in the past three years.

Save as disclosed above, as at the date of this announcement, Mr. NG does not have any interests in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong) which are required to be disclosed pursuant to Part XV of the SFO.

Save as disclosed in this announcement, Mr. NG has confirmed that there is no other information required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Listing Rules, nor is there any other matter that needs to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to express its warmest welcome to Mr. NG on his appointment as the chief executive officer.

By Order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 3 July 2026

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Directors are Dr. Qian Wei, Ms. Chin Yu and Mr. Lou Yongbin; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Kwok Che Chung and Dr. Zhao Yubiao.